A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents
- 1 July 1999
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 84 (1) , 46-50
- https://doi.org/10.1016/s0002-9149(99)00190-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ranolazine Increases Active Pyruvate Dehydrogenase in Perfused Normoxic Rat Hearts: Evidence for an Indirect MechanismJournal of Molecular and Cellular Cardiology, 1996
- Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat HeartsCirculation, 1996
- Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heartCardiovascular Research, 1994
- Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.Circulation, 1994
- Protective effects of ranolazine in guinea‐pig hearts during low‐flow ischaemia and their association with increases in active pyruvate dehydrogenaseBritish Journal of Pharmacology, 1993
- Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardiumEuropean Journal of Clinical Pharmacology, 1990
- Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusionBritish Journal of Pharmacology, 1990